Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 6:13:951376.
doi: 10.3389/fpsyt.2022.951376. eCollection 2022.

The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients

Albert Danan  1 , Eric C Westman  2 , Laura R Saslow  3 , Georgia Ede  4
Affiliations

The Ketogenic Diet for Refractory Mental Illness: A Retrospective Analysis of 31 Inpatients

Albert Danan et al. Front Psychiatry. .

Abstract

Background and hypothesis: The robust evidence base supporting the therapeutic benefit of ketogenic diets in epilepsy and other neurological conditions suggests this same metabolic approach may also benefit psychiatric conditions.

Study design: In this retrospective analysis of clinical care, 31 adults with severe, persistent mental illness (major depressive disorder, bipolar disorder, and schizoaffective disorder) whose symptoms were poorly controlled despite intensive psychiatric management were admitted to a psychiatric hospital and placed on a ketogenic diet restricted to a maximum of 20 grams of carbohydrate per day as an adjunct to conventional inpatient care. The duration of the intervention ranged from 6 to 248 days.

Study results: Three patients were unable to adhere to the diet for >14 days and were excluded from the final analysis. Among included participants, means and standard deviations (SDs) improved for the Hamilton Depression Rating Scale scores from 25.4 (6.3) to 7.7 (4.2), P < 0.001 and the Montgomery-Åsberg Depression Rating Scale from 29.6 (7.8) to 10.1 (6.5), P < 0.001. Among the 10 patients with schizoaffective illness, mean (SD) of the Positive and Negative Syndrome Scale (PANSS) scores improved from 91.4 (15.3) to 49.3 (6.9), P < 0.001. Significant improvements were also observed in metabolic health measures including weight, blood pressure, blood glucose, and triglycerides.

Conclusions: The administration of a ketogenic diet in this semi-controlled setting to patients with treatment-refractory mental illness was feasible, well-tolerated, and associated with significant and substantial improvements in depression and psychosis symptoms and multiple markers of metabolic health.

Keywords: bipolar disorder; depression; diet therapy; inpatients; ketosis; mental disorders; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

EW received consulting fees from Hill United Health and founded Adapt Your Life, Inc. (equity interest)—both companies founded on low-carbohydrate-diet principles—and received royalties for books that recommend a carbohydrate-restricted diet. GE reports stock options in DietDoctor.com, a company founded on low-carbohydrate principles. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Change in Clinical Global Impressions Severity Scale (CGI-S) Over Time. Severity of illness was assessed in 27 of 28 patients using the CGI-S. The CGI-S is rated on a scale of 1 to 7, with 1 indicating normal and 7 indicating extreme illness. Following the KD intervention, CGI-S had improved in all 27 patients, with 12 of 27 (44%) achieving a CGI-S of 1 (clinical remission).
Figure 2
Figure 2
Changes in Psychotropic Medication. Changes in the number and/or dosage of psychotropic medications associated with KD intervention are represented in this figure. The majority (64%) of participants were discharged on less medication.
See this image and copyright information in PMC

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. (2018) 392:1789-858. 10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed
    1. World Health Organization . Depression. (2021). Available online at: https://www.who.int/news-room/fact-sheets/detail/depression (accessed September 20, 2021).
    1. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. . Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. (2006) 163:217–24. 10.1176/appi.ajp.163.2.217 - DOI - PubMed
    1. Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. (2019) 19:247. 10.1186/s12888-019-2222-4 - DOI - PMC - PubMed
    1. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. . Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. (2017) 174:927–42. 10.1176/appi.ajp.2017.16121358 - DOI - PubMed